Compare Rush Street Interactive Inc (RSI) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rush Street Interactive Inc vs Zimmer Biomet Holdings Inc — how do they compare? Rush Street Interactive Inc trades at $19.29 (market cap $2.35B), while Zimmer Biomet Holdings Inc trades at $89.6 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 7.2× Rush Street Interactive Inc's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Rush Street Interactive Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Rush Street Interactive Inc for 13 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| RSI | ZBH | |
|---|---|---|
Market Cap | $2.35B | $16.95B |
Volume | 2,219,374 | 2,505,240 |
Sector | Consumer Cyclical | Health |
52-Week High | $34.52 | $103.98 |
52-Week Low | $15.89 | $79.58 |
Typical Hold Time | 13 Days | 89 Days |
Enterprise Value | $2.01B | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RSI trades at $19.32, down 4.55% today, with bearish technical signals from moving averages but neutral oscillators. The company reported mixed quarterly earnings, beating in Q1 and Q2 2026 but missing in Q4 2025. Revenue grew to $1.13B in 2025 with a net income margin of 2.33%, though profitability faces pressure as margins are expected to compress slightly in 2026. Analyst sentiment remains strongly positive with a consensus price target of $34.88, representing significant upside potential from current levels.
The stock presents a compelling opportunity given the substantial analyst upside target, but faces near-term headwinds from technical weakness and margin compression. Key risks include competitive pressures in online gaming and execution challenges in maintaining growth momentum. Institutional buying activity, including BlackRock's $448M investment in August 2026, provides confidence in the long-term thesis despite current price volatility.
Zimmer Biomet (ZBH) trades at $88.70, up 0.24% on the day, with a bearish technical outlook but strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.07 exceeding expectations. Revenue growth remains steady, reaching $8.23B in 2025, while profitability metrics like a 69.87% gross margin and 9.48% net margin reflect operational efficiency. Recent corporate news includes a $0.24 quarterly dividend declaration and leadership promotions aimed at accelerating commercial transformation.
The investment outlook is mixed, with analyst consensus leaning hold (52.38%) but a price target of $103.11 suggesting 16% upside. Key opportunities include sustained earnings beats and strategic initiatives, while risks involve rising debt levels, competitive pressures, and technical bearish signals. The stock's current valuation at a P/E of 21.57 appears reasonable relative to growth prospects, but investors should weigh fundamental strength against near-term technical weakness and macroeconomic headwinds in the healthcare sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Rush Street Interactive Inc
Rush Street Interactive, Inc. is a digital gaming and sports betting company operating in the regulated U.S. and international markets. The company owns and operates online casino (iGaming) and sports wagering platforms, including BetRivers and PlaySugarHouse brands. RSI focuses on providing a secure and high-quality online gaming experience, leveraging its proprietary technology platform and commitment to responsible gaming.
Read more on RSI →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
